AbbVie Reports meta-analysis Data for Tralokinumab in Hemophilia B

AbbVie today announced meta-analysis results for tralokinumab in patients with hemophilia B. The study demonstrated that tralokinumab improves progression-free survival compared to standard of care or placebo. These results provide important insights into the treatment of hemophilia B and support the continued development of tralokinumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.